Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Artemisinin combination therapy for the treatment of uncomplicated malaria includes artemether plus lumefantrine, artesunate plus amodiaquine, artesunate plus mefloquine, artesunate plus sulfadoxine-pyrimethamine and dihydroartemisinin plus piperaquine. These drugs are safe and efficacious at present. The emergence of artemisinin resistant parasites in SE Asia means that there is a need to optimise drug dosing and investigate novel therapies to maintain the impressive reduction in malaria mortality which has been seen in the past decade.

Original publication

DOI

10.1586/17512433.2014.907523

Type

Journal article

Journal

Expert Rev Clin Pharmacol

Publication Date

05/2014

Volume

7

Pages

299 - 316

Keywords

Animals, Antimalarials, Artemisinins, Clinical Trials as Topic, Drug Therapy, Combination, Humans, Malaria, Falciparum, Molecular Structure, Pharmacovigilance, Plasmodium falciparum